IRIDEX Corporation (IRIX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $12.12M
Last updated: Nov 17, 2026 at 10:43 AM ET
IRIDEX Corporation (IRIX) Valuation Multiples
IRIDEX (IRIX) trades at 0.2x sales and 3.3x book value. Its P/S of 0.2x is below its 5-year median of 0.6x. Its forward P/E is 769.2x.
Current Multiples
Its enterprise value is 108.8x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 769.2x |
| Price to sales | 0.2x |
| Price to book | 3.3x |
| EV/EBITDA | 108.8x |
| PEG | N/A |
| FCF yield | -16.7% |
Historical Medians
Against its 10-year medians, its P/S is 75.0% below 0.8x and its P/B is 6.5% above 3.1x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 0.2x | 0.6x | 0.8x |
| P/B | 3.3x | 3.7x | 3.1x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 0.4x in 2025 to 3.1x in 2016. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.14 | 0.4x | 4.0x |
| 2024 | $1.68 | 0.6x | 13.3x |
| 2023 | $2.81 | 0.9x | 4.8x |
| 2022 | $2.01 | 0.6x | 1.9x |
| 2021 | $6.11 | 1.8x | 4.2x |
| 2020 | $2.51 | 1.0x | 2.0x |
| 2019 | $2.23 | 0.7x | 1.4x |
| 2018 | $4.70 | 1.3x | 2.1x |
| 2017 | $7.62 | 2.1x | 2.9x |
| 2016 | $14.06 | 3.1x | 3.7x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IRIX
What is IRIX's forward P/E ratio?
IRIDEX has a forward P/E ratio of 769.2x.
Is IRIX stock overvalued?
GNG's valuation label for IRIX is Undervalued.
What is IRIX's price to sales ratio?
IRIDEX has a price to sales ratio of 0.2x.
IRIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts